ArticleJournal of Alzheimer's disease : JAD2017
Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Article in Journal of Alzheimer's disease : JAD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.JAMA neurology · 2020 · on this mapTrial
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer's Disease clinical trial.Nature communications · 2025Article
- Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study.The journal of prevention of Alzheimer's disease · 2025Article
- Low serum serotonin is associated with functional decline, mild behavioural impairment and brain atrophy in dementia-free subjects.Brain communications · 2025Article
- Employing Informatics Strategies in Alzheimer's Disease Research: A Review from Genetics, Multiomics, and Biomarkers to Clinical Outcomes.Annual review of biomedical data science · 2024Review
- Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.Journal of neurology · 2024Article
- Importance of Serum Albumin in Deep Learning-Based Prediction of Cognitive Function Data in the Aged Using a Basic Blood Test.Advances in experimental medicine and biology · 2024Article
- Importance of serum albumin in machine learning-based prediction of cognitive function in the elderly using a basic blood test.Frontiers in neurology · 2024Article
- Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairment.Frontiers in cell and developmental biology · 2024Article
- Detection and treatment of Alzheimer's disease in its preclinical stage.Nature aging · 2023Review
- Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.Brain : a journal of neurology · 2022Article
- Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study.Medicina (Kaunas, Lithuania) · 2022Article
- Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.Brain communications · 2022Article
- Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data.Frontiers in neurology · 2022Article
- Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- A peripheral lipid sensor GPR120 remotely contributes to suppression of PGDJournal of neuroinflammation · 2021Article
- Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.Neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIdentifying older adults at risk of cognitive decline represents a challenge as Alzheimer's disease (AD) modifying therapies move toward preclinical stages.
objectiveTo investigate the relationship between AD biomarkers and subsequent change in cognition in a cohort of cognitively intact older adults.
methods84 cognitively normal subjects (mean age 72.0 years, 59% women) were recruited through the Massachusetts Alzheimer's Disease Research Center and the Harvard Aging Brain Study and followed over 3 years. Measurements of amyloid-β 1-42 (Aβ42), total Tau (t-Tau), and Tau phosphorylated at threonine 181 (p-Tau181) in the cerebrospinal fluid (CSF) at study entry were available in all cases. Baseline brain MRI, FDG-PET, and PiB-PET data were available in the majority of participants. Relationship between baseline AD biomarkers and longitudinal change in cognition was assessed using Cox proportional hazard regression and linear mixed models.
results14% participants increased their global Clinical Dementia Rating (CDR) score from 0 to 0.5 during follow-up. A CDR score increase was associated with higher baseline CSF t-Tau and p-Tau181, higher global cortical PiB retention, and lower hippocampal volume. The combination of high CSF t-Tau and low Aβ42 or low hippocampal volume was more strongly related to cognitive outcome than each single biomarker. Higher CSF t-Tau was the only biomarker associated with subsequent decline in MMSE score.
conclusionsBaseline CSF t-Tau and p-Tau181, in vivo amyloid load, and hippocampal volume were all independently associated with future decline in cognition. The discriminatory ability of these biomarkers to predict risk of cognitive decline, however, was only modest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.